New Study: 99% of All Covid Prior Infections Resulted in 'Natural Immunity' That Lasted at Least 650 Days

“My Johns Hopkins research team is leading a long-term study of natural immunity because the NIH and CDC are not doing it," the lead researcher had promised.

Johns Hopkins university this week dropped a quiet bombshell of a study that went widely ignored in the mainstream media.

Dr. Marty Makary, spearheading a team at Johns Hopkins to do the work that the CDC and NIH refuse to do, showed that 99% of unvaccinated people known to have Covid infections had robust "natural immunity" that did not diminish for at least 650 days.

Results
Of 1580 individuals invited to undergo serologic testing, 816 (52%) did so between September 24, 2021, and November 5, 2021. Participants had a mean age of 48.0 years, 421 (52%) were women, and 669 (82%) were White (Table). Fourteen percent reported routine mask use in public. Anti-RBD and anti-N antibody presence/absence were correlated (95%; Cohen κ=0.908).

Among 295 reported COVID-confirmed participants, 293 (99%) tested positive for anti-RBD antibodies (≥250 U/mL, 44%; ≥500 U/mL, 27%; ≥1000 U/mL, 15%). A median of 8.7 (IQR, 1.9-12.9; range, 0-20) months passed since reported COVID-19 diagnosis. The median anti-RBD level among those who tested positive was 205 (IQR, 61-535) U/mL. There was no evidence of association between time after infection and antibody titer (0.8% increase [95% CI, –2.4% to 4.2%] per month, P = .62) (Figure).

Among 275 reported COVID-unconfirmed participants, 152 (55%) tested positive for anti-RBD antibodies (≥250 U/mL, 18%; ≥500 U/mL, 12%; ≥1000 U/mL, 6%). The median level among those who tested positive was 131 (IQR, 35-402) U/mL.

Among 246 reported no-COVID participants, 11% tested positive for anti-RBD antibodies (≥250 U/mL, 2%; ≥500 U/mL, 2%; ≥1000 U/mL, 2%). The median level among those who tested positive was 82 (IQR, 19-172) U/mL.

The charts included in the study reveal the story. As you can see, for three different types of important antibodies, about 95% of people with prior infections retained all three. 99% had the anti-RBD positive type of antibody.